Compounded peptides are unsafe

This objection is genuinely important, and the answer to it is not what either the marketers or the critics typically present. The objection is right that a peptide ordered from an unregulated international research-chemical supplier is not the same product as the FDA-approved branded drug. Purity, potency, sterility, residual solvent, identity, and stability all vary across suppliers; some published analyses of street-market peptides have found products that contained the wrong peptide entirely, or contained no peptide at all, or contained the right peptide at a different concentration than labeled. This site does not link, recommend, or grade vendors precisely because the failure modes are real and the available data is not robust enough to support a public ranking. But "compounded peptides are unsafe" obscures three distinctions that matter. First, compounding pharmacy versus research-chemical supply are not the same thing. A 503A or 503B compounding pharmacy in the United States operates under FDA oversight, produces compounded preparations to USP standards, requires a valid prescription from a licensed clinician, and is liable for the product it ships. A research-chemical supplier shipping "for research use only" labeled material from an offshore lab operates under no equivalent oversight. The objection's "compounded peptides" usually refers to one or the other interchangeably, but they sit in different regulatory and quality-control universes. Second, the FDA's own posture on compounding has been fluid. Several peptides this site covers are unavailable through US compounding pharmacies as of recent FDA action — semaglutide is the prominent recent example following the Wegovy / Ozempic shortage resolution in 2024 — while others remain available under specific conditions through specialist clinicians. The legal and regulatory status of compounded peptide supply varies substantially by jurisdiction and by peptide. Third, the alternative to compounded supply is not always "the branded drug at the licensed dose for the licensed indication." For peptides that have no FDA approval anywhere — most of this site's corpus — the choice is between unregulated supply and not using the peptide at all. Pretending that the branded-drug option exists when it does not is a category error that misrepresents the actual decision space. Where the critic has a real point: anyone considering a peptide outside its FDA-approved indication should treat sourcing-quality concerns as serious, not theoretical. Identity verification (third-party COA on the lot, ideally), sterility for any injectable preparation, and storage and reconstitution practices all bear on whether the peptide a person is administering is actually the molecule the literature describes. The "research chemical" framing the gray market uses is not protective rhetoric — it is a legal disclaimer designed to externalize the safety burden, and any reader who treats it as anything else is misreading the market. Where the critic loses the thread: collapsing US compounding pharmacy supply, international research-chemical supply, and FDA-approved branded drugs into a single category called "compounded peptides" produces a sentence that is uninformative about any specific decision a reader actually faces. The honest framing is "sourcing quality varies enormously, and the differences across the spectrum from a 503B pharmacy to an unregulated international supplier are larger than the differences between any two of those endpoints and the branded drug itself."